ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0326

Apolipoprotein L1 (APOL1) in African-American SLE: Frequency and Clinical Associations

Michelle Petri1, Romy Kallas2, Jessica Li3, Laurence Magder4 and Daniel Goldman1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Lankenau Medical Center, Lankenau, PA, 3Johns Hopkins University, Baltimore, MD, 4University of Maryland, Baltimore, Baltimore, MD

Meeting: ACR Convergence 2021

Keywords: genetics, Lupus nephritis, race/ethnicity, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: The APOL1 gene is implicated in induction of TLR3 agonists and interferons as well as in autophagy. Two genetic variants, G1 (2 single nucleotide polymorphisms) and G2 (6 base pair deletion) have been selected evolutionarily as protective against Trypanosoma. These APOL1 high risk allelles are associated with progression to end stage renal disease (ESRD), including lupus nephritis, and in one study with avascular necrosis in SLE. We examined the association of APOL1 in ESRD, avascular necrosis, atherosclerotic events and pulmonary fibrosis in African-American SLE.

Methods: APOL1 G1 (rs73885319 and rs60910145) and G2 (rs71785313) genetic variants were genotyped in 294 SLE African American patients in the Hopkins Cohort using TaqMan assays (Thermofisher Scientific, Waltham MA ). APOL1 variants were classified as G1/G1 homozygous (in our dataset, G/G), G2/G2 homozygous (-/-), compound heterozygous G1/G2 (G/T or A/G AND TTATAA/-), G0/G1 heterozygous (G/T or A/G), or G0/G2 heterozygous (TTATAA/-). Based on the variants, patients were stratified into groups with 0, 1, or 2 risk alleles. To address the association between APOL1 group and the three outcomes, we used Kaplan Meier approach to estimate the distribution of time to outcomes from date of birth and log-rank test to compute the p-value. Cox regression was used to estimate the hazard ratio and adjust the relationships. The follow up for each patient ended at the patient’s last cohort visit, or at the time of their first event.

Results: 294 African American patients were included in the analysis. 275 (93.5%) were female. The frequency of two copies of the APOL1 risk allele was 12.2% (Table 1). There was a higher proportion of patients with smoking history in the group with 2 risk alleles compared to the low risk groups (Table 2). There was an association with ESRD, but not with AVN, pulmonary fibrosis or cardiovascular events (Table 3).

Conclusion: Our study showed a significantly higher risk of progression to renal failure/ESRD among those with at least one risk allele, with a hazard ratio of 3.50 (p=0.0234 after adjusting for sex, ever smoking and hypertension). We did not find an association between APOL1 risk alleles and avascular necrosis/ atherosclerotic events/pulmonary fibrosis. Our analysis included adjustment for smoking, as it is a risk factor for all the outcomes, and included larger numbers of African-American patients and outcomes than previous studies.

Table 1: Frequency of the alleles and genotypes of APOL1

Table 2: Patient characteristics based on APOL1 genotype

Table 3: Relationships between events and APOL1 risk alleles (>=1 vs. 0)


Disclosures: M. Petri, Alexion, 1, Amgen, 1, Astrazeneca, 1, 5, Aurinia, 5, 6, Eli Lilly, 5, Emergent Biosolutions, 1, Exagen, 5, Gilead Biosciences, 2, GSK, 1, 5, IQVIA, 1, Idorsia Pharmaceuticals, 2, Janssen, 1, 5, Merck EMD Serono, 1, Momenta Pharmaceuticals, 2, PPD Development, 1, Sanofi, 2, Thermofisher, 5, UCB Pharmaceuticals, 2; R. Kallas, None; J. Li, None; L. Magder, None; D. Goldman, None.

To cite this abstract in AMA style:

Petri M, Kallas R, Li J, Magder L, Goldman D. Apolipoprotein L1 (APOL1) in African-American SLE: Frequency and Clinical Associations [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/apolipoprotein-l1-apol1-in-african-american-sle-frequency-and-clinical-associations/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/apolipoprotein-l1-apol1-in-african-american-sle-frequency-and-clinical-associations/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology